Patients With HCV, Chronic Kidney Disease Less Likely to Receive Antivirals
Individuals with CKD and HCV infection achieve high cure rates with newer anti-HCV treatment regiments.
For patients with hepatitis B virus, the presence of resistance-associated substitutions does not affect the outcome of therapy.
In children with immune-tolerant chronic HBV, combination entecavir/peginterferon for 48 weeks rarely led to loss of HBeAg with suppression of HBV DNA.
A new nucleotide analog is a pangenotypic HCV nonstructural protein 5B inhibitor that is well tolerated when administered in single and multiple doses.